Guardant Health (NASDAQ:GH) Announces Earnings Results

Key Points

• Guardant Health reported quarterly EPS of -$0.29, beating the -$0.75 consensus, and revenue of $361 million, up 36% and above estimates. The company raised its 2026 revenue outlook to $1.36 billion–$1.37 billion.
• Shield test volume surged 246% to 83,000, with payer decisions expected to expand coverage to about 100 million people by 2027; oncology testing volume also grew 58%.
• Margins improved and adjusted EBITDA losses narrowed, supporting the goal of cash-flow breakeven by the end of 2027. However, Guardant raised its full-year free-cash-flow-burn outlook to $205 million–$220 million, partly due to delayed CMS-related payments.

Guardant Health (NASDAQ:GH - Get Free Report) posted its earnings results on Thursday. The company reported ($0.29) EPS for the quarter, beating the consensus estimate of ($0.75) by $0.46, FiscalAI reports. The company had revenue of $360.98 million for the quarter, compared to the consensus estimate of $350.72 million.

Here are the key takeaways from Guardant Health's conference call:

• Revenue growth accelerated, and Guardant raised its 2026 outlook. Third-quarter revenue increased 36% to $361 million, prompting the company to raise full-year revenue guidance to $1.36 billion–$1.37 billion, or approximately 38%–40% growth.
• Shield screening showed strong adoption and expanding coverage. Shield volume rose 246% to 83,000 tests, while new payer decisions are expected to bring coverage to about 100 million people by 2027; management raised its full-year Shield volume and revenue outlook.
• Oncology growth was supported by rising test volumes and product milestones. Oncology volume increased 58%, with Reveal volumes more than doubling; Guardant also received FDA approval for ESR1 monitoring, submitted Guardant360 Tissue for FDA review, and expects to launch Reveal Ultra clinically before year-end.
• Cost improvements and lower cash burn supported the path toward profitability. Non-GAAP gross margin improved to 67%, Shield cost per test fell to $330—below the company’s year-end target—and adjusted EBITDA loss narrowed to $37 million; Guardant reiterated its goal of company-wide cash-flow breakeven by the end of 2027.
• Full-year free-cash-flow-burn guidance increased. Guardant now expects $205 million–$220 million of burn, partly because $10 million–$15 million in Guardant360 Liquid CDx payments are expected to shift into 2027 due to a CMS billing-system delay; the company also plans continued investment in commercial expansion.

Guardant Health Price Performance

Shares of Guardant Health stock traded down $15.56 on Thursday, hitting $153.01. The company had a trading volume of 4,072,426 shares, compared to its average volume of 2,200,776. The business has a 50-day simple moving average of $170.02 and a 200-day simple moving average of $131.62. The company has a market cap of $20.53 billion, a PE ratio of -43.84 and a beta of 1.67. Guardant Health has a 52 week low of $74.55 and a 52 week high of $191.05.

Analyst Ratings Changes

Several equities research analysts have weighed in on GH shares. UBS Group increased their target price on Guardant Health from $175.00 to $225.00 and gave the stock a "buy" rating in a research report on Wednesday, September 9th. Roth Capital initiated coverage on shares of Guardant Health in a report on Thursday, October 22nd. They set a "buy" rating and a $200.00 price target for the company. JPMorgan Chase & Co. upped their price target on shares of Guardant Health from $185.00 to $195.00 and gave the stock an "overweight" rating in a research report on Friday, July 31st. TD Cowen reaffirmed a "buy" rating on shares of Guardant Health in a report on Tuesday, August 25th. Finally, Guggenheim lifted their price objective on shares of Guardant Health from $190.00 to $200.00 and gave the company a "buy" rating in a research report on Thursday, October 1st. One investment analyst has rated the stock with a Strong Buy rating, twenty-four have given a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $191.00.

Insider Activity

In other Guardant Health news, Director Alex Azar, II sold 826 shares of the company's stock in a transaction that occurred on Wednesday, September 16th. The stock was sold at an average price of $175.00, for a total value of $144,550.00. Following the completion of the sale, the director directly owned 825 shares in the company, valued at $144,375. This represents a 50.03% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Amirali Talasaz sold 37,500 shares of the stock in a transaction on Friday, August 21st. The shares were sold at an average price of $169.16, for a total value of $6,343,500.00. Following the transaction, the chief executive officer directly owned 37,500 shares of the company's stock, valued at approximately $6,343,500. The trade was a 50.00% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 163,060 shares of company stock valued at $27,538,217 over the last 90 days. Corporate insiders own 5.60% of the company's stock.

About Guardant Health

Guardant Health, Inc NASDAQ: GH is a precision oncology company that develops blood-based tests and data solutions designed to help detect cancer, guide treatment decisions and monitor patients over time. Its technologies analyze circulating tumor DNA and other molecular information from blood samples, supporting more accessible and less invasive alternatives to some tissue-based testing approaches.

The company's products include Guardant360, which helps identify genomic alterations in advanced cancers and may inform targeted treatment selection; Guardant360 Response, designed to assess a patient's response to therapy; and Guardant Reveal, which is used to detect minimal residual disease and recurrence risk in certain cancers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.